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Aim: Vasospasm is one of the most important factors that influence the successful treatment of ruptured
intracranial aneurysm. We studied if vasospasm following subarachnoidal haemorrhage (SAH) can be alleviated
by dexmedetomidine in an animal model.
Materials and Methods: Experimental SAH was induced in 12 of 18 New Zealand rabbits by intracisternal
injection of autologous blood. Control animals (sham SAH, n = 6) received intracisternal injection of the
respective volume of physiological saline solution. Forty eight hours after the operation, rabbits in sham SAH
and SAH-alone (n = 6) groups were infused intravenously with 0.9% sodium chloride for 2 h, whereas rabbits
in SAH-dexmedetomidine group (n = 6) received intravenous infusion of 5 µg/kg per h dexmedetomidine for
2 h. All rabbits were sacrificed with penthotal 24 h after infusions. Basilar arteries were isolated and processed
for histology.
Results: The histological specimens revealed evidence of arterial narrowing and vascular wall thickening in
both SAH-alone and SAH-dexmedetomidine groups. The wall thickness of basilar artery significantly increased
and lumen diameter significantly reduced in SAH-alone group in comparison with basilar arteries from other
groups (P < 0.05). SAH-dexmedetomidine group revealed attenuation of vasospasm formed after 72 h.
Conclusions: Our study showed that vasospasm is attenuated by dexmedetomidine administered after
vasospasm is formed in a rabbit model.
Key Words: Dexmedetomidine, subarachnoid haemorrhage, vasospasm.

Deneysel Subaraknoid Kanama Sonras› Oluﬂan
Vazospazm›n Dexmedetomidine ile Azalt›lmas›
Amaç: Vazospazm kanam›ﬂ intrakranyal anevrizmalar›n baﬂar›l› tedavisini etkileyen en önemli faktörlerden
birisidir. Biz bu çal›ﬂmam›zda subaraknoid kanama (SAK) sonras› geliﬂen vazospazm›n dexmedetomidinle
önlenip önlenemeyece¤ini hayvan modelinde çal›ﬂt›k.
Yöntem ve Gereç: On sekiz Yeni Zelanda tavﬂan›n›n 12’sine kendi kanlar› intrasisternal ﬂekilde verilerek
deneysel SAK oluﬂturuldu. Kontrol grubundaki (Sham-SAK, n = 6) hayvanlara ayn› miktarda fizyolojik salin
solusyonu intrasisternal enjekte edildi. Operasyondan 48 saat sonra sham-SAK ve yaln›z-SAK (n = 6) gruplar›na
intravenöz olarak 2 saat boyunca % 0,9 Sodyum Klor solüsyonu verildi. Yine operasyondan 48 saat sonra SAKdexmedetomidine (n = 6) grubuna 2 saat süresince dexmedetomidine (saatte 5 µg/kg) verildi. Bu iﬂlemlerden
24 saat sonra tüm hayvanlar pentotal infüzyonu sonras› sakrifiye edildi. Basilar arterleri ç›kart›ld› ve histolojik
çal›ﬂma için haz›rland›.
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Bulgular: Histolojik sonuçlar yaln›z-SAK ve SAK-dexmedetomidine gruplar›nda arteryel daralma ve damar
duvar›nda kal›nlaﬂma gösterdi.Yaln›z-SAK grubu di¤er gruplar ile karﬂ›laﬂt›r›ld›¤›nda basilar arter duvar
kal›nl›¤› artmas› ve damar lumen çap›n›n azalmas› istatiksel olarak anlaml›yd› (P < 0.05). SAKdexmedetomidine grubunda 72 saat sonra vazospazm›n azald›¤› gözlendi.
Sonuç: Bizim çal›ﬂmam›z, tavﬂan modelinde vazospazm oluﬂtukdan sonra dexmedetomidine uygulaman›n
vazospazm› azaltt›¤›n› gösterdi.
Anahtar Sözcükler: Dexmedetomidine, subaraknoid kanama, vazospazm
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* This study was previously presented as a poster presentation at the Congress of the European Society of
Anaesthesiology in Vienne, 2005.
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Introduction

Materials and Methods

Subarachnoid haemorrhage (SAH) is most commonly
caused by a ruptured aneurysm in the circle of Willis.
Vasospasm, occurring prior to, during, and after surgery
(1), is one of the most important factors that influence
successful treatment of ruptured intracranial aneurysm.
Blood and blood breakdown products are considered as
the important spasmogens in the etiology of vasospasm
(2-7). A thickened hyperplastic arterial wall is also taken
into consideration as a cause of vasospasm after SAH with
a primary vascular spasm (2,3,6). It has been
demonstrated that vasospasm can be influenced by many
factors, among which the possible role of the sympathetic
nervous system has been suggested (8).

This study was approved by the Animal Ethics
Committee of Afyon Kocatepe University. One day before
surgery, rabbits were fasted and pretreated with an
antibiotic, cefazoline (Cefozin, 50 mg/kg, intravenously
(I.V.), Bilim, Turkey).

Dexmedetomidine is recently used for sedation in the
intensive care units. It inhibits central sympathetic
discharge, decreases arterial blood pressure and heart
rate and causes sedation due to its α2 agonistic effects.
Dexmedetomidine has also been reported to protect
against incomplete ischemia in rats (9) and against focal
ischemia in rabbits (10). Neuroprotection of
dexmedetomidine is also shown in gerbil global ischemia
model (11). However, it failed to protect against severe
forebrain ischemia in rats (12). In these studies the
effects of dexmedetomidine on cerebral vasculature were
not reported.
Although another α2 agonist, clonidine, has been
shown to prevent chronic vasospasm (13),
dexmedetomidine is not suggested for patients with SAH.
In addition, since excessive sympathetic discharge is
proposed as the cause of vasospasm and α2
adrenoreceptor agonists have also been shown to reduce
ischemic damage possibly by attenuating the excessive
release of noradrenaline during energy failure (14),
potential antivasospastic effect of dexmedetomidine is
assumed. We aimed to study antivasospastic effect of
dexmedetomidine after post-SAH vasospasm has
developed, considering the fact that most of the patients
are admitted to physicians after SAH has been
established. We used rabbit SAH model because of the
anatomical similarity of sympathetic innervation of rabbit
cerebral arteries compared to human ones (15). In our
study, we wanted to find out if vasospasm following
subarachnoidal haemorrhage can be alleviated by
dexmedetomidine.
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The study was carried out on 18 male New Zealand
rabbits (weighing 1500-2000 gr). Animals were
anaesthetized with intramuscular (I.M.) Xylazine HCI
(15mg/kg) / ketamine (25mg/kg), and placed on a heated
surgical table to maintain body temperature at 37 ºC.
After anesthesia, 2 L/min of oxygen was given to avoid
hypoxia. Rabbits were randomly enrolled into 1 of the 3
groups: sham-SAH (n = 6), SAH-alone (n = 6), and SAHdexmedetomidine (n = 6) group. All rabbits were fixed in
a prone position and a midline incision between the ears
over the external occipital protuberance was made
caudally to reach cisterna magna. After the first incision,
dermal and subdermal tissues, fascia and paravertebral
muscles were dissected. The atlanto-occipital membrane
was dissected and a 27-gauge needle was inserted
through the dura and the arachnoid membrane into the
cisterna magna. In the control group 0.9 ml/kg of 0.9%
NaCl was given into cerebrospinal fluid (CSF). In 2 SAH
groups, nonheparinized arterial blood (0.9 ml/kg)
obtained from the ear artery was injected into the
cisterna magna. In order to permit a good distribution of
the blood around the basal intracranial arteries, rabbit
was kept in a head down position from the onset of the
injection until 10 min after injection. This procedure is
similar to the method of Solomon et al. (16). After
rabbits recovered from anesthesia, they were left for 48
h in their cages for the establishment of vasospasm.
After 48 h, all rabbits were reanesthetized with I.M.
Xylazine HCI (15mg/kg) / ketamine (25mg/kg) and placed
on a heated surgical table to maintain body temperature
at 37 ºC. After anesthesia was introduced, 2 L/min of
oxygen was given. Half of the initial dose of anesthetics
was given to maintain anesthesia when the rabbits were
starting to move or their heart beat increased by 10%.
One of the ear arteries was cannulated to monitor arterial
blood pressure and one of the ear veins was cannulated
for intravenous fluid infusion. Electrocardiography,
arterial blood pressure, peripheral oxygen saturation, and
body temperature were monitored (Datex Ohmeda Type
F-CU8, Helsinki, Finland) throughout the procedure.
Control and SAH-alone group received I.V. infusion of 5
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mL/kg of 0.9% NaCl per hour for 2 h, whereas SAHdexmedetomidine
group
received
5µg/kg
dexmedetomidine per hour as an I.V. infusion for 2 h.
Total dose of 10 µg/kg of dexmedetomidine was infused
in 0.9% NaCl at a rate of 5 mL/kg per hour (17).
All rabbits were sacrificed with 20 mg/kg penthotal
after 24 h following the infusions, i.e. 72 h after SAH.
Their brains were removed immediately for the
histopathological study.
Histopathological examination
The samples were collected by cutting the brainstem
including basilar artery and examined by a pathologist
who was blinded to the study groups. Basilar arteries
were harvested from the midline between basilarposterior cerebral artery junction and basilar-vertebral
artery junction and fixed in 10% neutral formalin
solution. After dehydration procedures, the samples were
embedded in paraffin; 4–6 µm sections were cut with a
microtome and stained with hematoxylin and eosin
(H&E). Mounted slides were evaluated and photographed
using a light microscope (Olympus BX51, Tokyo, Japan).
Image analysis
The circumferences of internal elastic lamina and
tunica adventitia of each basilar artery were marked and
measured with an image analysis system. During marking
the internal elastic lamina, the convolutions were included
to the circumference of the basilar artery. The internal
(lumen) and external diameters were calculated using
mathematic formula for the measure of circumference.
The wall thickness of the artery was calculated by
subtraction of internal from external diameter. These
measurements were made at 3 locations on the basilar
artery; near the vertebrobasilar junction, at the midpoint,
and close to the basilar tip. The wall thickness and lumen
diameters were calculated for each vessel as the
arithmetic mean of values obtained at these 3 locations.
The investigator who performed these measurements
was blinded to the conditions. The system used is
composed of a PC with hardware and software (ImagePro Plus 5.0, Media Cybernetics, USA) for image
acquisition and analysis, a Spot Insight QE (Diagnostic
Instruments, USA) camera and an optical microscope. The
method requires preliminary software procedures of
spatial calibration (micron scale) and setting of color
segmentation for quantitative color analysis.
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Statistical Analysis
All data are presented as mean ± standard deviation
(SD). Statistical analysis was performed on a personal
computer using SPSS for Windows (SPSS Inc., USA). The
data of physiological monitoring and histopathological
images were considered to be nonparametric; therefore,
they were treated using the Kruskal–Wallis H test
analysis. The inter-group comparisons were performed
using Mann–Whitney U tests. P < 0.05 was considered
statistically significant.

Results
The histology of basilar arteries from 3 groups are
shown in Figure 1. Light microscopy appearance of these
arteries was normal in control group. The endothelium
had a continuous monolayer overlying a thin convoluted
internal elastic lamina (Figure 1a). In SAH-alone and SAHdexmedetomidine groups, basilar arteries showed certain
morphological changes such as increase of the intimal
convolution, desquamation of the endothelial cells, and
vacuolar degeneration of the tunica muscularis. There
was also evidence of arterial narrowing and vascular wall
thickening in both SAH-alone and SAH-dexmedetomidine
groups (Figures 1b and 1c).
The luminal diameters and thickness of basilar arteries
are shown in Table 1. The luminal diameters were 598 ±
15.3 µm, 346 ± 9.2 µm, and 553 ± 11.6 µm in control,
SAH-alone, and SAH-dexmedetomidine groups,
respectively. The luminal diameters of basilar arteries in
SAH-alone group were significantly smaller than in
control and SAH-dexmedetomidine groups (P < 0.05).
The thickness of the basilar artery was 42 ± 1.2 µm, 54
± 1.3 µm, and 40±1.1 µm in control, SAH-alone, and
SAH-dexmedetomidine groups, respectively. Basilar
artery wall thickness was significantly increased in SAHalone group in comparison with the control and SAHdexmedetomidine groups (P < 0.05).
There were no differences between the groups in the
mean heart rhythm, mean arterial blood pressure,
peripheral oxygen saturation, intracranial and body
temperature measured during the study (Table 2).
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Figure 1. Cross section photograph of basillary arteries. A) Control group: Showing control basilar artery, a continuous monolayer of endothelium
formed, overlying the thin convoluted smooth muscle cells surrounded the intima. H&E ×100. B) SAH-alone group: Significant degree of
reduction in luminal diameter and increase in wall thickness is seen. H&E ×100. C) SAH-Dexmedetomidine group: The wall thickness and
luminal diameter of the rat basilar arteries were increased compared to those in the SAH group. H&E ×100.

Table 1. Comparisons of wall thickness and luminal diameter of basilar artery in 3 groups. Values are
represented as mean ± SD, and n = 6 for all groups (Mann-Whitney U Test).
Group

Diameter of basilar artery
(µm)

Thickness of basilar artery
(µm)

598 ± 15.3

42 ± 1.2

II- SAH-alone

346 ± 9.2

54 ± 1.3

III- SAH-Dexmedetomidine

553 ± 11.6

40 ± 1.1

I- Control

P values
I-II

P < 0.05

P < 0.05

I-III

N.S.

N.S.

II-III

P < 0.05

P < 0.05

NS: Nonspecific (P > 0.05)

Discussion
The effects of dexmedetomidine on basilar artery
after experimental SAH were studied by intracisternal
injection of autologous blood in a rabbit model. Diameters
of basilar artery were measured in fixed histological
sections. Our data provide that selective α2 adrenergic
agonist, dexmedetomidine, may have antivasospastic
effect in experimental SAH.
It is suggested that central sympathetic system is
overstimulated and it also causes a stress response to the
stressor after SAH. Following central sympathetic
discharge, hypertension occurs and cell metabolism
194

increases. Finally, stimulation of α-adrenoceptors causes
vasospasm (15). Sympathetic stimulus that induces the
formation of adrenaline and noradrenaline also causes
abnormal sensitivity of the cerebral vasculature to
increased catecholamines on arterial walls (18). Increased
catecholamine levels were also suggested as the cause of
degeneration that is seen in cerebral vascular system
(18). Some researchers also suggest that plasma
noradrenaline levels may be a reliable indicator of the
outcome of vasospastic patients after SAH (19). There
are also some reports demonstrating advantageous
systemic and cerebral effects of α and β receptor
blockade after subarachnoid haemorrhage (20).
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Table 2: Physiological parameters of the groups.
Times
(minute)
Group I

Group II

Group III

MHR / minute

MAP

SaO2

ICT

BT

0-30

170±0.5

80.2±0.3

98.1±0.2

36.5±0.01

36.5±0.02

30-60

151±0.3

76.2±0.4

98.4±0.3

36.6±0.01

36.5±0.01

60-90

150±0.6

74.3±0.2

98.6±0.2

36.5±0.03

36.6±0.02

90-120

152±0.8

75.4±0.6

99.1±0.2

36.6±0.02

36.7±0.02

0-30

172±0.4

81.5±0.4

97.4±0.2

36.5±0.02

36.5±0.03

30-60

152±0.3

78.4±0.6

98.1±0.1

36.5±0.03

36.6±0.01

60-90

154±0.6

77.3±0.3

98.2±0.2

36.6±0.01

36.6±0.02

90-120

153±0.5

78.3±0.5

98.6±0.3

36.6±0.02

36.6±0.03

0-30

169±0.7

75.2±0.5

98.0±0.1

36.5±0.02

36.5±0.01

30-60

148±0.3

74.5±0.4

98.2±0.3

36.5±0.03

36.6±0.02

60-90

150±0.8

73.5±0.5

98.5±0.3

36.6±0.03

36.6±0.01

90-120

152±0.5

74.2±0.2

99.0±0.1

36.6±0.01

36.7±0.02

MHR, mean heart rhythm; MAP, mean arterial pressure (mmHg); SaO2, Oxygen saturation (%); ICT, intracranial
temperature (°C); BT, body temperature (°C)

Participation of increased discharge of peripheral
sympathetic nerve endings in delayed vasospasm after
SAH was also suggested by Bunc et al. (21). This study
demonstrated that exclusion of the peripheral
sympathetic nervous system (upper gangliectomy), on the
one hand, and of the systemic sympathetic nervous
system (α-blocker phenoxybenzamine), on the other, was
also effective in preventing vasospasm in the same SAH
model (21).
Alpha2 agonist clonidine showed its antivasospastic
effect due to the blockade of the central noradrenergic
discharge in conjunction with peripheral sympathetic
inhibition (13). Sympathetic discharge blockade by
clonidine has been demonstrated to effectively prevent
chronic vasospasm in an experimental study (13).
However, the clinical study of α2 agonist clonidine showed
that plasma noradrenaline levels were not affected by
intravenous infusion in SAH patients (22). Lambert et al.
(22) also suggested that lack of response to clonidine may
be due to the route of administration, the dose of the
drug, or the patient group studied.
Alpha2 adrenergic receptors are widely distributed
within the cerebral vasculature, and it has been proposed
that specific cerebral vasoconstrictor responses are
induced by activation of these receptors (23).

Accordingly, dexmedetomidine decreased cerebral blood
flow in both isoflurane- and halothane-anesthetized dogs
without influencing the metabolic rate for oxygen
(24,25). Moreover, it was also demonstrated that
dexmedetomidine constricted cerebral vessels in
pentobarbital-anesthetized dogs (26).
Prielipp et al. (27) showed that dexmedetomidineinduced sedation in young, healthy, normotensive
volunteers is associated with the decrease of regional and
global cerebral blood flow. However, it is unclear
whether the same findings will be seen in hypertensive,
older, and anesthetized patients, patients with traumatic
brain injury, or patients with other intracranial or
metabolic alterations of cerebral autoregulation. In an in
vitro study, Bryan et al. (28) demonstrated α2 adrenergic
receptor-mediated dilation of rat middle cerebral arteries
that involved NO and a pertussis toxin sensitive G protein
as mediators.
NO level decreases in the first hour after SAH and the
half-life reduces because of the oxidative stress. In the
following hours, overproduction of NO results in
overconsumption, and this process activates the
production of free radicals (29). Additionally, excessive
noradrenaline release after SAH has a potential role in the
formation of free radicals (21). Dexmedetomidine may
195
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inhibit the excessive catecholamine release via activating
the presynaptic α-2 adrenoceptors and also may inhibit
the formation of free radicals and oxidative stress after
SAH.
According to the study of Kovacic et al. (30) and
biphasic vasospasm model, the vasospasm increased at
the 48th hour and between days 5 and 8. We
administered dexmedetomidine at the 48th hour after
SAH. Although, functional changes are seen earlier in
vasospastic arteries, this preliminary study is based on
morphological results. The morphological results of our
study showed that the wall of basilar arteries were
normal in control group. However, in SAH-alone and
SAH-dexmedetomidine groups, the effect of vasospasm
was seen in the wall of basilar arteries.
There was also evidence of arterial narrowing and
vascular wall thickening (Figure 1b and 1c). Many
conflicting results in dexmedetomidine induced recovery
of SAH may suggest that peripheral sympathetic blockade
is more important than central sympathetic blockade. Our
results that showed recovery of vasospasm in contrast to
continuation of histopathological changes on arterial wall
may support this hypothesis. Further studies focusing on
peripheral sympathetic discharge are needed. Our study

Turk J Med Sci

points out benefits of dexmedetomidine in SAH. Although
prevention of SAH is achieved in rabbits by clonidine, by
another α2 agonist, or by starting to establish it as SAH
is forme, this is not the case in most clinical
circumstances. Mostly, patients are admitted to
physicians after they have experienced SAH in different
neurological status. Our study shows that
dexmedetomidine may be effective for alleviating
vasospasm after the insult of SAH.

Conclusion
Although we have studied the effect of
dexmedetomidine 48 h after experimental SAH, its
effects after chronic vasospasm may also be studied.
These studies may give us hope that dexmedetomidine
may be used for its antivasospastic effects, as well.
However, human studies should be done to prove
antivasospastic effects of dexmedetomidine and its effects
on the outcome of patients after SAH. As a result, the
major finding of the present study indicates that
dexmedetomidine may alleviate vasospasm 48 h after
experimental SAH. However, detailed studies are
necessary to examine these preliminary findings and to
clarify the mechanisms of action.
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